CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million

CH BIOTECH SER (08037) announced that on May 18, 2026, the seller (an affiliated company of the company, Central Laboratory (Group) Limited) intends to sell all the issued share capital of Standard Pathological Laboratory and all the issued share capital of Zokuji Health to the buyer (Mr. Chan Kam Fuk) for a total price of HK$3.5 million, subject to the restrictions of the terms of the sale agreement. The main business of Standard Pathological Laboratory is to provide medical laboratory testing services and health check services. The main business of Zokuji Health is to provide health check services. Upon completion, Standard Pathological Laboratory and Zokuji Health will no longer be subsidiaries of the group, and their financial performance will no longer be consolidated into the group's financial performance. The group regularly reviews its assets and businesses and considers asset sales when appropriate offers are made, continuously striving to improve its business and financial performance. As of March 31, 2026, the unaudited net liabilities of the target company were approximately HK$29.013 million, indicating a severe state of insolvency. To divest from this underperforming business segment, optimize the group's business performance, and avoid the continued financial burden of the target company's ongoing losses, the sale transaction will allow the company to reallocate resources to support overall strategic development.